135 related articles for article (PubMed ID: 33856410)
1. Development and Evaluation of a Method to Correct Misinterpretation of Clinical Trial Results With Long-term Survival.
Hsu CY; Lin EP; Shyr Y
JAMA Oncol; 2021 Jul; 7(7):1041-1044. PubMed ID: 33856410
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Cancer Survival Associated With Immune Checkpoint Inhibitors After Statistical Adjustment: A Systematic Review and Meta-analyses.
Lin EP; Hsu CY; Berry L; Bunn P; Shyr Y
JAMA Netw Open; 2022 Aug; 5(8):e2227211. PubMed ID: 35976648
[TBL] [Abstract][Full Text] [Related]
3. Cox Proportional Hazard Ratios Overestimate Survival Benefit of Immune Checkpoint Inhibitors: Cox-TEL Adjustment and Meta-Analyses of Programmed Death-Ligand 1 Expression and Immune Checkpoint Inhibitor Survival Benefit.
Lin EP; Hsu CY; Chiou JF; Berry L; Horn L; Bunn P; Yang JC; Yang PC; Adjei AA; Shyr Y
J Thorac Oncol; 2022 Dec; 17(12):1365-1374. PubMed ID: 36049656
[TBL] [Abstract][Full Text] [Related]
4. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
5. Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials.
Cavillon A; Pouessel D; Houédé N; Mathevet F; Dauxois JY; Chevreau C; Culine S; Delord JP; Porcher R; Filleron T
Eur Urol; 2024 Mar; 85(3):293-300. PubMed ID: 36849297
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Treatment Effects and Long-term Benefits in Immune Checkpoint Inhibitor Trials Using the Flexible Parametric Cure Model: A Systematic Review.
Filleron T; Bachelier M; Mazieres J; Pérol M; Meyer N; Martin E; Mathevet F; Dauxois JY; Porcher R; Delord JP
JAMA Netw Open; 2021 Dec; 4(12):e2139573. PubMed ID: 34932105
[TBL] [Abstract][Full Text] [Related]
7. Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067.
Regan MM; Mantia CM; Werner L; Tarhini AA; Larkin J; Stephen Hodi F; Wolchok J; Postow MA; Stwalley B; Moshyk A; Ritchings C; Re S; van Dijck W; McDermott DF; Atkins MB
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34799400
[TBL] [Abstract][Full Text] [Related]
8. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
9. Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma.
Gibson EJ; Begum N; Koblbauer I; Dranitsaris G; Liew D; McEwan P; Yuan Y; Juarez-Garcia A; Tyas D; Pritchard C
J Med Econ; 2019 Jun; 22(6):531-544. PubMed ID: 30638416
[No Abstract] [Full Text] [Related]
10. Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition.
Naik GS; Waikar SS; Johnson AEW; Buchbinder EI; Haq R; Hodi FS; Schoenfeld JD; Ott PA
J Immunother Cancer; 2019 Mar; 7(1):89. PubMed ID: 30922394
[TBL] [Abstract][Full Text] [Related]
11. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
12. Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.
Regan MM; Werner L; Rao S; Gupte-Singh K; Hodi FS; Kirkwood JM; Kluger HM; Larkin J; Postow MA; Ritchings C; Sznol M; Tarhini AA; Wolchok JD; Atkins MB; McDermott DF
J Clin Oncol; 2019 Dec; 37(35):3350-3358. PubMed ID: 31498030
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma.
Federico Paly V; Kurt M; Zhang L; Butler MO; Michielin O; Amadi A; Hernlund E; Johnson HM; Kotapati S; Moshyk A; Borrill J
MDM Policy Pract; 2022; 7(1):23814683221089659. PubMed ID: 35356551
[TBL] [Abstract][Full Text] [Related]
14. The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety.
Wu Y; Shi H; Jiang M; Qiu M; Jia K; Cao T; Shang Y; Shi L; Jiang K; Wu H
Int J Cancer; 2017 Dec; 141(12):2562-2570. PubMed ID: 28833119
[TBL] [Abstract][Full Text] [Related]
15. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.
Laino AS; Woods D; Vassallo M; Qian X; Tang H; Wind-Rotolo M; Weber J
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581042
[TBL] [Abstract][Full Text] [Related]
16. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
17. Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial.
Branchoux S; Sofeu CL; Gaudin AF; Kurt M; Moshyk A; Italiano A; Bellera C; Rondeau V
ESMO Open; 2022 Feb; 7(1):100340. PubMed ID: 34929616
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.
Everest L; Shah M; Chan KKW
JAMA Netw Open; 2019 Jul; 2(7):e196803. PubMed ID: 31290990
[TBL] [Abstract][Full Text] [Related]
19. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
20. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
Wu B; Shi L
JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]